Gut pH Dysregulation
The upstream initiating event — and why restoring it is the first priority
How gastric pH is normally controlled
Parietal cells in the gastric mucosa produce hydrochloric acid through the H⁺/K⁺-ATPase proton pump, driven by carbonic anhydrase generating the hydrogen ions required. This process depends on an intact zinc-containing carbonic anhydrase enzyme, adequate vagal acetylcholine stimulation of muscarinic M3 receptors on parietal cells, and histamine signaling through H2 receptors. Normal fasting gastric pH is approximately 1.5–2.0. Normal fed-state pH remains below 4.0 — the level required to keep pepsin active.
Multiple founding conditions described on Molecular Origins independently reduce parietal cell HCl output: zinc depletion from OCP use removes the carbonic anhydrase cofactor; H. pylori alkalinises the stomach through urease-generated ammonia; chronic sympathetic dominance withdraws vagal tone; proton pump inhibitor (PPI) therapy directly suppresses the proton pump; carbonic anhydrase and proton pump gene variants reduce structural acid production capacity from birth.
The self-perpetuating pH loop
pH dysregulation is self-reinforcing from the earliest cascade steps. Gut SST-28, driven into overexpression by downstream opioid peptide accumulation, suppresses gastrin — the primary driver of parietal cell HCl production. The same cascade that began with inadequate acid production generates a mechanism that suppresses acid production further. This is why normalising gastric pH requires addressing both the upstream founding conditions and the downstream SST-28 overexpression that perpetuates the low-acid environment.
Pepsin Failure and Opioid Peptide Accumulation
A single enzymatic failure that initiates two parallel cascade arms simultaneously
Pepsin biochemistry and proline bond specificity
Pepsin is an aspartic protease that cleaves peptide bonds adjacent to aromatic and hydrophobic amino acid residues — most critically the proline-containing bonds that lock essential amino acids within casein and gluten proteins. Its catalytic mechanism requires protonation of two aspartic acid residues in its active site, which occurs optimally at pH 1.5–2.5 and is abolished above pH 4.0. Above this threshold the enzyme undergoes irreversible conformational denaturation of its active site geometry — not mere inhibition but structural deactivation.
Small intestinal proteases — trypsin, chymotrypsin, elastase — do not substitute for pepsin's proline bond specificity. When pepsin fails, the rigid corkscrew geometry of proline-bonded peptide fragments resists all downstream proteolysis and the fragments enter systemic circulation intact through the compromised mucosal barrier.
Casomorphin, gliadorphin, and the two parallel arms
Beta-casomorphin-7 (from bovine casein) and gliadorphin (from wheat gluten) are the primary exorphin fragments generated by incomplete proline bond cleavage. Both bind mu-opioid receptors in the gut wall and brain, initiating parallel biochemical consequences through two entirely distinct receptor systems.
Mu-opioid receptor activation → persistent CCK-A overstimulation → gut SST-28 (intestinal D-cell somatostatin) tonically overexpressed → suppression of secretin, VIP, gastrin, and motilin → deepened pH dysregulation and impaired gut motility. Full detail →
Casomorphin and gliadorphin occupy the adenosine deaminase (ADA) binding site on CD26 / DPP-IV → adenosine accumulates inside lymphocytes → methionine synthase rate-limited → methylation cycle stalls → S-adenosylmethionine (SAMe) depletion. Full detail →
Arm A — CCK-A Overactivation and Gut SST-28 Dysregulation
How persistent opioid receptor activation converts episodic digestive regulation into chronic hormonal suppression
Normal CCK-A episodic cycle vs chronic opioid-driven overactivation
Under normal physiology, duodenal I-cells release CCK in response to luminal fat and protein. CCK-A receptors on vagal afferent nerve fibres signal satiety and trigger pancreatic enzyme release. Intestinal D-cell SST-28 provides episodic negative feedback — activated by CCK to suppress further CCK, gastrin, secretin, and VIP as digestion winds down. The cycle resets between meals.
Casomorphin and gliadorphin fragments are not food stimuli — they occupy mu-opioid receptors on enteroendocrine cells continuously, not episodically. The body interprets this as a persistent, meal-independent CCK-A activating signal and upregulates CCK synthesis accordingly. The SST-28 feedback system is then driven into tonic overexpression — not as a physiological regulator but as a chronically activated suppressor of the entire digestive hormone cascade.
What SST-28 tonic overexpression suppresses
| Suppressed hormone | Normal function lost | Clinical consequence |
|---|---|---|
| Gastrin | Parietal cell HCl stimulation | Further pH elevation — compounds and perpetuates pepsin inactivation |
| Secretin | S-cell release triggered by luminal acid below pH 4.2; bicarbonate production; pancreatic fluid secretion | Secretin goes unreleased — S-cells intact but pH threshold never reached. Compound loss of central secretin effects (cerebellum, hippocampus) |
| VIP (gut) | Smooth muscle relaxation; peristaltic coordination; mucosal blood flow | Reduced gut motility — constipation, delayed gastric emptying, irregular transit |
| Motilin | Migrating motor complex — inter-meal gut clearance | Impaired gut emptying between meals; bacterial overgrowth risk |
| Gastric acid (secondary) | Protein digestion; mineral ionisation; pathogen barrier | Self-reinforcing pH loop — the downstream consequences of pepsin failure deepen its upstream cause |
The gut–brain SST asymmetry: In the gut, SST-28 from intestinal D-cells is tonically overactive — suppressing the digestive hormone cascade. In the brain, SST-14 from cortical and hypothalamic interneurons is being silenced — failing to coordinate oxytocin, VIP, and secretin release. Same gene. Same precursor. Opposite dysfunction. Sequential causation.
Arm B — CD26 Blockade, Adenosine Accumulation, and Methylation Failure
How the same opioid peptides initiate a parallel methylation and energy crisis through an entirely separate receptor system
CD26 as the adenosine deaminase docking station
CD26 (dipeptidyl peptidase IV / DPP-IV) is a membrane protein on lymphocyte immune cells that serves as the binding site for adenosine deaminase (ADA) — the enzyme that converts intracellular adenosine to inosine, clearing the cellular fatigue signal. Casomorphin and gliadorphin physically occupy the ADA docking site on CD26, preventing ADA from binding and executing adenosine clearance. Mercury, streptokinase, and genetic CD26 variants block the same site by the same mechanism — their effects are additive.
Four systems failing simultaneously from SAMe depletion
COMT requires SAMe to methylate and inactivate catecholamines. SAMe depletion impairs dopamine and norepinephrine regulation, compounding the precursor deficit from tryptophan/tyrosine loss at P2.
T-cell and B-cell differentiation and inflammatory resolution depend on histone and DNA methylation. SAMe depletion locks immune cells in pro-inflammatory states, sustaining the cytokine load that drives subsequent cascade steps.
Cytosine methylation patterns govern inflammatory and synaptic gene expression. SAMe depletion compromises these patterns, producing epigenetic drift toward dysregulated gene expression states.
SAMe is required for phosphatidylcholine synthesis — the primary phospholipid of mitochondrial membranes. Depletion degrades membrane integrity, reducing electron transport chain efficiency and ATP production — the energy substrate SST-14 tonic firing requires.
LPS Translocation, IDO1, and NF-κB
How gut barrier compromise converts a local digestive failure into systemic immune activation
LPS — the bacterial cell wall toxin that enters systemic circulation
Lipopolysaccharide (LPS) is a structural component of the outer membrane of gram-negative bacteria — present in enormous quantities in the normal gut flora as a commensal constituent. Under intact gut barrier conditions, LPS remains confined to the gut lumen. When the intestinal mucosal barrier is compromised — by the same intact proline-bonded peptide fragments that penetrated the mucosal wall in P2 — LPS enters the portal circulation and reaches systemic macrophages, hepatic Kupffer cells, brain endothelial cells, and resident brain microglia.
LPS binds to the toll-like receptor 4 (TLR4)-MD-2-CD14 pattern recognition complex on all of these cell types. Even at picomolar concentrations, LPS-TLR4 engagement activates both MyD88-dependent and TRIF-dependent signalling cascades that converge on NF-κB. The result is production of IL-1β, IL-6, TNF-α, and IFN-γ in quantities that cannot be resolved by normal homeostatic mechanisms as long as the gut barrier remains compromised and LPS influx continues.
IDO1 — the tryptophan diversion enzyme
Indoleamine 2,3-dioxygenase 1 (IDO1) is strongly induced by the same cytokine environment generated by LPS-TLR4-NF-κB activation — particularly IFN-γ and TNF-α. IDO1 catalyses the first and rate-limiting step of tryptophan catabolism through the kynurenine pathway: the oxidative cleavage of the indole ring of tryptophan to produce N-formylkynurenine and then kynurenine.
The consequence is dual and simultaneous. From supply: tryptophan is being continuously diverted away from serotonin synthesis — which depends on tryptophan as its sole dietary precursor — by IDO1. Combined with the pepsin-inactivation-driven tryptophan supply deficit established at P2, IDO1 produces the double tryptophan depletion: reduced supply from above, active diversion from below. From toxicity: the kynurenine pathway produces quinolinic acid, a potent endogenous N-methyl-D-aspartate (NMDA) receptor agonist, as a downstream metabolite — the mechanism of excitotoxic SST-14 interneuron pressure described at P5.
The kynurenine:tryptophan (K:T) ratio in plasma is the direct, quantitative measure of IDO1 activity. Launay et al. (2023, Translational Psychiatry, PMID 38071324, n=271) directly measured IDO1 activation, NAD⁺ levels, and plasma oxytocin in the same ASD cohort — establishing the hypothalamic consequences as a measured human outcome, not a theoretical inference.
The Kynurenine Pathway and SST-14 Excitotoxic Pressure
From tryptophan diversion to quinolinic acid, NMDA overactivation, and NAD⁺ depletion
Kynurenine pathway bifurcation
Kynurenine produced by IDO1 faces a metabolic bifurcation. The neuroprotective branch, catalysed by kynurenine aminotransferases, produces kynurenic acid — an NMDA receptor antagonist and neuroprotective compound. The neurotoxic branch, catalysed by kynurenine 3-monooxygenase (KMO) and driven by the same pro-inflammatory cytokines activating IDO1, produces 3-hydroxykynurenine and ultimately quinolinic acid (QUIN).
The inflammatory environment of immune-derived autism drives the bifurcation toward the neurotoxic branch. IFN-γ and TNF-α upregulate KMO, shifting kynurenine metabolism toward quinolinic acid production. The ratio of kynurenic acid to quinolinic acid — the neuroprotective:neurotoxic balance — is measurably shifted toward the neurotoxic side in ASD populations.
Quinolinic acid excitotoxicity and NAD⁺ depletion at SST-14 interneurons
Quinolinic acid is a structural analogue of glutamate that binds and activates NMDA receptors with high affinity. At concentrations produced by chronically active IDO1, quinolinic acid drives sustained NMDA receptor activation that forces calcium entry into neurons at rates exceeding their mitochondrial buffering capacity.
SST-14 interneurons are disproportionately vulnerable to this excitotoxic pressure for two reasons. First, they maintain tonic high-frequency firing — their continuous inhibitory output requires continuous ATP production. The mitochondrial calcium overload from NMDA overactivation directly impairs the ATP synthesis that tonic firing depends on. Second, the mitochondrial phosphatidylcholine depletion established by SAMe insufficiency at P3B has already degraded membrane integrity — reducing the resilience of mitochondria in precisely the cell population facing the greatest excitotoxic pressure.
Further downstream, quinolinic acid is converted to NAD⁺ as the terminal product of the kynurenine pathway — but under chronic IDO1 activation, NAD⁺ consumption by mitochondrial stress response mechanisms exceeds the capacity of the pathway to replace it. The result is cellular NAD⁺ depletion that further compromises the ATP production that SST-14 tonic firing requires — a self-reinforcing energy failure in the cells most vulnerable to the excitotoxic pressure producing it.
SST-14 Interneuron Silencing — Four Simultaneous Mechanisms
The convergent node where all upstream pathways arrive — and where the biological latch engages
SST-14 interneurons in the cortex, hippocampus, and hypothalamus are suppressed at four mechanistically distinct and simultaneously operating levels. Each is necessary but not sufficient alone — their convergence is what produces the persistent, self-reinforcing silencing that defines immune-derived autism and distinguishes it from transient inflammatory episodes.
| Mechanism | Molecular pathway | Source cascade step |
|---|---|---|
| 1. Excitotoxic metabolic depletion | Quinolinic acid → NMDA activation → calcium overload → mitochondrial ATP failure → tonic firing failure | P5 — Kynurenine / IDO1 |
| 2. Transcriptional suppression via NF-κB → CREB | LPS → TLR4 → NF-κB → CREB inhibition → somatostatin gene CRE deactivated → SST-14 mRNA production falls | P4 — LPS / NF-κB |
| 3. Adenosine-mediated cAMP suppression | CD26 blockade → adenosine accumulation → A1/A2A receptor activation → Gαi → adenylyl cyclase ↓ → cAMP ↓ → protein kinase A (PKA) ↓ → CREB phosphorylation ↓ → SST-14 transcription ↓ | P3B — CD26 / Methylation |
| 4. Autoantibody surface receptor jamming | Chronic adaptive immune activation → autoantibodies against SST-14 interneuron surface proteins → membrane signal transduction impaired even when SST-14 peptide production is partially maintained | P4 — NF-κB immune activation |
The mechanistic significance of four simultaneous pathways: Addressing any single suppression mechanism — reducing inflammatory cytokines, restoring cAMP, clearing autoantibodies — produces partial relief but not resolution. The three remaining mechanisms continue operating. Complete SST-14 functional recovery requires reducing the suppressive burden across multiple pathways concurrently — which is the rationale for the multi-component biomarker-stratified intervention described on Intervention Logic.
A1 Astrocyte Polarisation and the Loss of Neural Plasticity
How microglial activation converts the brain's support architecture from synaptogenic to synaptosuppressive
From microglial activation to astrocyte phenotype shift
Activated microglia — driven by LPS-TLR4-NF-κB signalling and released from SST-14 anti-inflammatory inhibitory control — produce the three signals that Liddelow et al. (Nature 2017) identified as sufficient and necessary to drive astrocytes from their A2 homeostatic state to the A1 reactive phenotype: IL-1α, TNF-α, and complement component C1q.
A2 homeostatic astrocytes produce hevin (SPARCL1), brain-derived neurotrophic factor (BDNF), and glypicans 4 and 6 — the synaptogenic proteins that drive thalamocortical relay synapse formation and support the neural plasticity that enables learning, social development, and behavioral flexibility. They maintain glutamate clearance from the synaptic cleft, preventing excitotoxic spillover. They support the blood-brain barrier.
A1 reactive astrocytes suppress all of these functions. They withdraw hevin and SPARCL1, reducing thalamocortical synaptogenesis. They reduce BDNF production. They impair glutamate clearance, compounding the excitotoxic pressure on SST-14 interneurons established at P5. They produce pro-inflammatory mediators that further sustain microglial activation — closing a feedback loop between the two glial cell types.
The A1 polarisation is not permanent. Liddelow et al. established that the A1 reactive state is maintained by ongoing microglial IL-1α/TNF-α/C1q signalling and reverses when those signals are removed. Neural plasticity — the cellular substrate for learning, social development, and behavioral recovery — can be restored by interventions that reduce microglial A1-inducing activation. The clinical assumption that the adult brain's developmental window is irreversibly closed is mechanistically unjustified in this cascade framework.
Thalamocortical vulnerability — why hevin loss specifically matters
Hevin (SPARCL1) is required for the formation and maintenance of thalamocortical relay synapses — the connections through which all primary sensory information (except olfaction) is relayed from thalamic nuclei to primary sensory cortices. Thalamocortical synapses are specifically and disproportionately dependent on hevin for their formation and stability compared to other synapse types.
When A1 astrocyte polarisation withdraws hevin, thalamocortical relay connectivity is preferentially impaired. Combined with the SST-14 interneuron silencing in the thalamic reticular nucleus (TRN) that removes the gating function on sensory transmission, the result is two-level sensory processing failure in series: impaired thalamic gating combined with impaired thalamocortical relay connectivity. This structural explanation accounts for the long-range under-connectivity observed in ASD neuroimaging — not as a primary developmental anomaly but as a secondary consequence of A1 astrocyte withdrawal of synaptogenic support from the hevin-dependent connectivity layer.
Neuropeptide Cascade Disruption
Oxytocin, VIP, and secretin — and why prior trials failed in unselected populations
Oxytocin — motivational deficit, not structural social incapacity
SST-14 interneurons in the hypothalamic paraventricular nucleus (PVN) modulate the pulsatile timing and amplitude of oxytocin release in response to social and safety signals. SST-14 silencing blunts and decouples this release from social context — producing a deficit in the neurochemical signal that makes social interaction feel rewarding and worth seeking.
Launay et al. 2023 measured plasma oxytocin, IDO1 activity (K:T ratio), and NAD⁺ levels in the same cohort of 271 ASD individuals — directly demonstrating the downstream hypothalamic oxytocin suppression as a measured consequence of IDO1 activation, not an inference. This finding also explains the consistent null result from unselected oxytocin trials: exogenous oxytocin cannot restore the pulsatile timing and social-contextual coupling that SST-14 interneuron coordination provides. Sikich et al. (NEJM 2021, SOARS-B, n=290) confirmed the null result definitively. The mechanism — not the molecule — is the target.
VIP — G-protein cascade failure across four biological systems
Vasoactive intestinal peptide signals through the canonical G-protein cascade: VIP receptor → Gαs → adenylyl cyclase → cAMP → PKA → CREB → target gene expression. In immune-derived autism this signalling chain has been disrupted at three independent points simultaneously: adenosine-driven Gαi suppresses adenylyl cyclase through A1/A2A receptors; SST-14 silencing removes the contextual inhibitory coordination required for phasic VIP signalling; NF-κB directly suppresses CREB at the transcriptional endpoint.
VIP signals through the same disrupted cAMP/CREB pathway in four distinct biological systems — losing coordinating function in all four simultaneously:
- Circadian clock — VIP synchronises the suprachiasmatic nucleus cellular oscillators; loss produces the fragmented, arrhythmic sleep documented in 40–80% of ASD individuals
- Sensory cortical gain control — VIP-driven disinhibition provides context-appropriate sensory gain modulation through interneuron network dynamics
- Gut motility — VIP drives enteric smooth muscle relaxation and peristaltic coordination
- Immune regulation — VIP suppresses pro-inflammatory cytokine production; its loss removes an anti-inflammatory brake at the moment the inflammatory cascade most requires it
Secretin — compound failure and the Horvath paradox
Secretin faces disruption from two independent directions simultaneously. From below: gut SST-28 tonic overexpression (P3A) has suppressed gastric acid output to the point where duodenal luminal pH never drops below the 4.2 threshold required for S-cell secretin release. The S-cells are structurally intact — they have been deprived of the acid signal that should trigger them. From above: SST-14 silencing removes the central neural coordination that secretin signalling requires for its brain-side effects.
This compound failure explains and rehabilitates the Horvath et al. 1998 observation — behavioral improvements in three autistic children receiving intravenous secretin during endoscopy. Intravenous delivery bypassed the blocked S-cell pH-dependent release mechanism entirely, delivering secretin directly to circuits that were genuinely secretin-deficient. The subsequent Cochrane review (2012) of 14 null RCTs confirms that unselected enrollment of heterogeneous populations diluted the responsive subgroup to statistical insignificance. Both findings are simultaneously correct: the mechanism is real and the unselected population trials were testing the wrong thing.
The Self-Reinforcing Biological Latch
Why the cascade persists — and why partial interventions produce transient improvement followed by relapse
SST-14 loss removes its own brake on the mechanisms suppressing it
SST-14 interneurons normally exert anti-inflammatory inhibitory tone on microglia and on the reactive astrocyte polarisation mechanism. When SST-14 output falls, this inhibitory brake is removed — and the mechanisms producing SST-14 silencing are themselves disinhibited. The latch closes:
- SST-14 loss → microglial reactivity increases → more IL-1α/TNF-α/C1q → deeper A1 astrocyte polarisation
- Deeper A1 polarisation → hevin/BDNF further withdrawn → thalamocortical connectivity further impaired
- Increased microglial cytokine production → NF-κB suppression of CREB deepens → SST-14 transcription further reduced
- Increased IDO1 activity → quinolinic acid rises → excitotoxic pressure on remaining SST-14 interneurons intensifies
- Excitatory disinhibition from SST-14 loss → more glutamate release → more NMDA receptor stimulation → more calcium overload in surviving SST-14 interneurons
- More gut SST-28 overexpression (from sustained opioid peptide load) → more gastric acid suppression → deeper pH dysregulation → more pepsin inactivation → more opioid peptides → more CD26 blockade
The cascade cannot self-correct because the mechanism that should initiate correction — SST-14 anti-inflammatory and inhibitory output — is the mechanism that has been disabled. This is the biological latch: a system whose corrective mechanism is its own failure product.
The clinical implication: Effective intervention requires interrupting the latch at multiple points simultaneously — not just the strongest driver, not just the most accessible biomarker. The three-state intervention framework on Intervention Logic and Immunoglobulin Therapy operationalises this principle into a biomarker-stratified clinical protocol.